The
CHARM study will evaluate the efficacy and safety of BIIB093 within 10
hours of a cerebral stroke. The primary endpoint is the improvement in
patients based on the modified Rankin Scale, a measurement of functional
outcome or disability of a patient at 90 days.
Although
the candidate failed to meet the primary endpoint in a phase II study,
it demonstrated potential improvement in functional outcomes and
mortality. With enrolment of first patient in the CHARM study, it is
still a long way ahead for a successful